Overview

A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

This was a multicenter, prospective, observational, open-label study. Patients meeting inclusion/exclusion criteria received treatment with treprostinil as recommended by their treating physicians and were followed according to standard of care. This observational study collected clinical data and biologic specimens from patients who were treated for portopulmonary hypertension (PoPH), with a goal of achieving hemodynamic parameters appropriate for orthotopic liver transplantation candidacy, including mean pulmonary arterial pressure (mPAP) less than 35 mmHg and pulmonary vascular resistance (PVR) less than 3 Wood-units (WU) at Week 24 in patients with severe PoPH.

Details

Lead Sponsor:

United Therapeutics

Collaborators:

Brigham and Women's Hospital
Emory University
University of California, Los Angeles
University of Kansas
University of Texas
University of Wisconsin, Madison

Treatments:

Treprostinil